Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License ...
In August, the U.S. Food and Drug Administration (FDA) stated that it is requiring an additional MRI scan for Alzheimer's patients receiving Leqembi (lecanemab), citing safety concerns over a rare but ...
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market ...
CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, ...
WASHINGTON (AP) — Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated ...
The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for ...
By Mariam Sunny April 29 (Reuters) - Biogen beat first-quarter expectations on Wednesday, as stronger sales of its ...
US biotech Biogen delivered a stronger-than-expected first quarter on Wednesday, with both revenue and earnings surpassing ...
Patients and physicians warn decision denies access for early-onset Alzheimer’s patients seeking disease-modifying therapies ...
Biogen cut its full-year profit forecast on Wednesday as it booked acquisition-related charges, although its first-quarter ...
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results